MX355299B - Inhibidores de cinasa de fosfoinositida 3 cristalina. - Google Patents

Inhibidores de cinasa de fosfoinositida 3 cristalina.

Info

Publication number
MX355299B
MX355299B MX2014010991A MX2014010991A MX355299B MX 355299 B MX355299 B MX 355299B MX 2014010991 A MX2014010991 A MX 2014010991A MX 2014010991 A MX2014010991 A MX 2014010991A MX 355299 B MX355299 B MX 355299B
Authority
MX
Mexico
Prior art keywords
solid crystalline
crystalline
kinase inhibitors
ynamide
pyrirnidin
Prior art date
Application number
MX2014010991A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010991A (es
Inventor
Walter Ferdinand Maria Filliers
Alex Herman Copmans
Rudy Laurent Maria Broeckx
Carina Leys
Patrick Hubert J Nieste
Filip Marcel C Vanhoutte
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355299(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of MX2014010991A publication Critical patent/MX2014010991A/es
Publication of MX355299B publication Critical patent/MX355299B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2014010991A 2012-03-13 2013-03-13 Inhibidores de cinasa de fosfoinositida 3 cristalina. MX355299B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13
PCT/GB2013/050624 WO2013136076A1 (en) 2012-03-13 2013-03-13 Crystalline pi3 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014010991A MX2014010991A (es) 2014-10-13
MX355299B true MX355299B (es) 2018-04-11

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010991A MX355299B (es) 2012-03-13 2013-03-13 Inhibidores de cinasa de fosfoinositida 3 cristalina.
MX2014010990A MX357170B (es) 2012-03-13 2013-03-13 Uso de sal metálica de ácido estárico o de estearil fumarato particulada para estabilizar una formulación farmacéutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014010990A MX357170B (es) 2012-03-13 2013-03-13 Uso de sal metálica de ácido estárico o de estearil fumarato particulada para estabilizar una formulación farmacéutica.

Country Status (35)

Country Link
US (3) US20150099768A1 (OSRAM)
EP (2) EP2825202B1 (OSRAM)
JP (3) JP2015509973A (OSRAM)
KR (2) KR20140141596A (OSRAM)
CN (2) CN104302650B (OSRAM)
AU (2) AU2013234081B2 (OSRAM)
CA (2) CA2864652A1 (OSRAM)
CL (2) CL2014002385A1 (OSRAM)
CO (2) CO7061079A2 (OSRAM)
CR (2) CR20140417A (OSRAM)
CY (1) CY1118565T1 (OSRAM)
DK (1) DK2834244T3 (OSRAM)
EA (2) EA023715B1 (OSRAM)
EC (2) ECSP14018142A (OSRAM)
ES (2) ES2650791T3 (OSRAM)
GT (2) GT201400182A (OSRAM)
HR (1) HRP20161383T1 (OSRAM)
HU (1) HUE029420T2 (OSRAM)
IL (2) IL233883A0 (OSRAM)
IN (2) IN2014MN02000A (OSRAM)
LT (1) LT2834244T (OSRAM)
MX (2) MX355299B (OSRAM)
MY (1) MY171125A (OSRAM)
NI (2) NI201400100A (OSRAM)
NZ (2) NZ627963A (OSRAM)
PE (2) PE20142342A1 (OSRAM)
PH (2) PH12014501713A1 (OSRAM)
PL (1) PL2834244T3 (OSRAM)
PT (1) PT2834244T (OSRAM)
SG (2) SG11201404522VA (OSRAM)
SI (1) SI2834244T1 (OSRAM)
TW (2) TWI586378B (OSRAM)
UA (1) UA115544C2 (OSRAM)
WO (2) WO2013136076A1 (OSRAM)
ZA (2) ZA201407374B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
HUE029420T2 (en) 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
EA201692456A1 (ru) 2014-07-09 2017-08-31 Арвен Иладж Санайи Ве Тиджарет А.Ш. Способ получения составов для ингаляции
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
MY204600A (en) * 2016-04-15 2024-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
CN101506211B (zh) 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
JP2009537158A (ja) 2006-05-24 2009-10-29 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 免疫原性の減少を伴った高親和性ヒトおよびヒト化抗−α５β１インテグリン機能阻害抗体
MX2009000107A (es) 2006-06-29 2009-01-23 Schering Corp Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
EA200901488A1 (ru) 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
TR201901644T4 (tr) 2010-09-30 2019-02-21 Chiesi Farm Spa İnhalasyon için kuru toz formülasyonlarında magnesyum stearat. kullanımı.
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
HUE029420T2 (en) 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors

Also Published As

Publication number Publication date
NZ628072A (en) 2015-08-28
TW201350139A (zh) 2013-12-16
IN2014MN01998A (OSRAM) 2015-08-14
ZA201407374B (en) 2016-10-26
JP2015509973A (ja) 2015-04-02
AU2013234081A1 (en) 2014-08-21
EP2834244A1 (en) 2015-02-11
CO7061079A2 (es) 2014-09-19
PE20141964A1 (es) 2014-12-01
IN2014MN02000A (OSRAM) 2015-08-14
EA201491675A1 (ru) 2014-12-30
PL2834244T3 (pl) 2017-01-31
CL2014002386A1 (es) 2015-02-27
HRP20161383T1 (hr) 2016-12-02
PE20142342A1 (es) 2015-01-16
CN104284679B (zh) 2017-08-04
PH12014501922A1 (en) 2014-11-24
ES2600705T3 (es) 2017-02-10
PT2834244T (pt) 2016-11-03
KR20140131971A (ko) 2014-11-14
ZA201407373B (en) 2016-10-26
KR20140141596A (ko) 2014-12-10
EA201491674A1 (ru) 2014-12-30
GT201400182A (es) 2015-09-17
US20150105408A1 (en) 2015-04-16
JP2015509972A (ja) 2015-04-02
WO2013136075A1 (en) 2013-09-19
CR20140417A (es) 2014-10-31
WO2013136076A1 (en) 2013-09-19
TWI586378B (zh) 2017-06-11
HK1203812A1 (en) 2015-11-06
JP6189874B2 (ja) 2017-08-30
UA115544C2 (uk) 2017-11-27
US20170239256A1 (en) 2017-08-24
IL233886A (en) 2017-12-31
CR20140416A (es) 2014-10-31
EA023715B1 (ru) 2016-07-29
CL2014002385A1 (es) 2015-01-09
CA2864643A1 (en) 2013-09-19
MX357170B (es) 2018-06-27
CN104302650B (zh) 2017-07-18
AU2013234080B2 (en) 2016-12-22
US20150099768A1 (en) 2015-04-09
CO7051030A2 (es) 2014-09-10
ES2650791T3 (es) 2018-01-22
EA025465B1 (ru) 2016-12-30
EP2834244B1 (en) 2016-08-10
HUE029420T2 (en) 2017-02-28
SI2834244T1 (sl) 2016-12-30
SG11201404519UA (en) 2014-10-30
HK1203487A1 (zh) 2015-10-30
JP2018008992A (ja) 2018-01-18
GT201400183A (es) 2015-07-08
NZ627963A (en) 2015-08-28
EP2825202A1 (en) 2015-01-21
CN104302650A (zh) 2015-01-21
CY1118565T1 (el) 2017-07-12
ECSP14018142A (es) 2015-06-30
TW201400484A (zh) 2014-01-01
MX2014010991A (es) 2014-10-13
US9642799B2 (en) 2017-05-09
IL233883A0 (en) 2014-09-30
NI201400101A (es) 2016-11-30
CA2864652A1 (en) 2013-09-19
PH12014501713A1 (en) 2014-10-13
NI201400100A (es) 2015-01-12
AU2013234080A1 (en) 2014-08-21
LT2834244T (lt) 2016-11-10
TWI617561B (zh) 2018-03-11
ECSP14018630A (es) 2015-09-30
DK2834244T3 (en) 2016-11-28
MY171125A (en) 2019-09-26
CN104284679A (zh) 2015-01-14
EP2825202B1 (en) 2017-09-06
AU2013234081B2 (en) 2017-02-02
MX2014010990A (es) 2014-10-13
SG11201404522VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
MX355299B (es) Inhibidores de cinasa de fosfoinositida 3 cristalina.
IL288009A (en) Use of proton tyrosine kinase inhibitors
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
ZA201209381B (en) The use of inhibitors of bruton's tyrosine kinase (btk)
MY150611A (en) P38 map kinase inhibitors
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
UA115320C2 (uk) Інгібітори кінази
IN2012DN02577A (OSRAM)
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
UA114531C2 (uk) Противірусні сполуки проти rsv
MX360246B (es) Composiciones y metodos para el tratamiento de la mielofibrosis.
WO2013004995A8 (en) Pyrimidinone compounds and their use
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
PH12014501278A1 (en) Kinase inhibitors
TH156276A (th) ตัวยับยั้ง pi3 ไคเนสที่เป็นผลึก
TN2014000218A1 (en) Kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration